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Background: Neuropsychiatric symptoms play an important role in diagnosing and clinical
follow-up of cognitive impairment and dementia.
Objective: We investigated the relationship between neuropsychiatric symptoms, cognitive
impairment, and dementia in Hispanics.
Methods: We included 529 participants (age ≥40 years) from the Maracaibo Aging Study with
standardized neuropsychiatric assessments, including the Neuropsychiatric Inventory (NPI). Based
on the Clinical Dementia Rating and the Mini-Mental State Examination scores, participants’
cognitive status was categorized into normal cognition, mild/moderate, and severe cognitive
impairment. Diagnosis of dementia was established in a consensus conference. Statistical analyses
included multivariable logistic regression models and area under the curve (AUC).

Author Manuscript

Results: The mean age of participants was 59.3 years, and 71.8% were women. The
proportion of dementia was 6.8%. Disturbed sleep, anxiety, and depression were the most
common neuropsychiatric symptoms in the study sample. In crude analyses, the proportions of
hallucinations, aberrant motor behavior, agitation/aggression, apathy, delusions, irritability, eating
disturbance, depression, and euphoria were differently distributed among cognitive status groups
(p < 0.05). After accounting for confounders, aberrant motor behavior and agitation/aggression
remained significantly associated with cognitive impairment and dementia (p < 0.05). The
inclusion of the NPI domains significantly improved the AUC to discriminate severe cognitive
impairment and dementia above of a basic model that included sex, age, education, alcohol,
obesity, serum glucose, total cholesterol, hypertension, and stroke.
Conclusion: Neuropsychiatric symptoms are associated with severe cognitive impairment and
dementia. The addition of NPI items to the global cognitive assessment might help early detection
of dementia in primary care settings.

Author Manuscript
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INTRODUCTION

Author Manuscript

Alzheimer’s disease (AD) and related dementias represent a major global health challenge
problem in older adults, with 40–50 million people currently living with dementia. In
addition, given the increased global longevity, communities, governments, and healthcare
systems are facing an exacerbated burden of dementias [1]. This situation demands
prevention strategies targeted to identify risk factors in the early stages of dementia that
delay the onset and reduce the poor outcomes associated with the disease’s clinical course.
To achieve this, the cognitive changes resembling “normal aging” and denoting dementia
onset should be properly differentiated [2]. The first line diagnostic evaluation is usually
primary care providers which rely on global cognitive assessment tools and short anamnesis
to collect information about the impact of cognitive changes on daily life activities to
determine whether further clinical assessment is needed. However, very frequently, this
information is not sufficient to properly identify cognitive decline and/or dementia. Because
of improved diagnostic accuracy [3, 4] and prediction of outcomes in patients with dementia
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[5], recognizing neuropsychiatric symptoms may be a valuable step in the primary care of
older adults.

Author Manuscript

The deficiency of clinical tools and the poorly understood race/ethnicity differences in
the epidemiology of dementias aggravates the diagnostic needs in low resource settings.
Hispanics are disproportionately affected by AD, with almost a two-fold elevated risk of
developing AD [6, 7] and earlier onset of the disease than non-Hispanic whites [8]. Yet
Hispanics are underrepresented in clinical research [9], leading to a lack of information
regarding the clinical course of dementia in this rapidly growing minority group. Given the
current gaps in the literature about dementia in Hispanics living in developing countries,
and the need for tackling early detection of dementia, we conducted the present study
to investigate the relationship of neuropsychiatric symptoms with cognitive impairment
and dementia in a population-based study of older Hispanic adults living in Maracaibo
City, Venezuela. Moreover, we tested the hypothesis that the inclusion of neuropsychiatric
information improves the sensitivity of a global cognitive assessment such as the Mini
Mental State Examination (MMSE) and the Clinical dementia Rating (CDR) to detect
clinically defined dementia.

MATERIALS AND METHODS
Study population

Author Manuscript
Author Manuscript

The Maracaibo Aging Study (MAS) is a longitudinal, prospective, community-based,
cohort study of individuals, ≥40 years old, residing in the Santa Lucia and Santa Rosa
neighborhoods, Maracaibo, Venezuela. The MAS initially included 2,439 subjects ≥55
years old, living in the community of Santa Lucia from 1998 to 2001, which were
followed until 2016, undergoing the same standardized assessments. In 2011, the MAS
was expanded to include 420 participants, ≥40 years old, living in Santa Rosa de Agua and
109 residing in Santa Lucía; the distance between the two communities is approximately
6 km. These two samples are relatively stable communities with a high density of
families of different socioeconomic conditions [10]. The MAS collected information about
demographic, clinical, nutritional, cardiovascular, cognitive, and social factors associated
with aging. For the present study, we included the 529 subjects recruited in 2011 with
available baseline data on the Neuropsychiatric Inventory (NPI) and cognitive evaluations,
including dementia assessment and MMSE. Detailed information regarding recruitment
strategy, study design, and sample characteristics have been previously reported [10, 11].
Informed consent was obtained for each participant or from a surrogate when appropriate.
The Institutional Review Board of the Cardiovascular Center at the University of Zulia in
Maracaibo approved the study.
Assessment of behavioral symptoms
The NPI rates each dementia-related behavioral symptom according to frequency (0—4
points), and severity (1–3 points), and the total score is calculated by multiplying the
frequency × severity [12]. The scores scale from 0 to 12 points. Eighty-two participants
(16.1%) were not able to respond to the NPI inquiries and a family member or
a caregiver provided the information about the presence, frequency, and severity of
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behavioral symptoms. Trained psychiatrists conducted the NPI interview. The NPI domains
included delusions, hallucinations, agitation/aggression, depression, anxiety, euphoria,
apathy, disinhibition, irritability, aberrant motor behavior, sleep disturbances, and eating
disturbances [12]. Subjects with an NPI score of zero were classified as “asymptomatic”,
whereas those with NPI scores ≥ 1 were classified as “symptomatic”.
Cognitive assessment and dementia diagnoses

Author Manuscript

Cognitive performance was assessed using the MMSE [13], and cognitive domains were
assessed using a full neuropsychological battery of cognitive tests administered by a
neuropsychologist [10]. The original MMSE has a maximum score of 30 points [14]. The
MMSE scores were divided into normal (24–30 points), low (18–23 points), and very-low
MMSE scores (≤17 points). We therefore categorized cognitive status by combining the
MMSE and the CDR scores (0.0, 0.5, 1.0, 2.0, and 3.0) [30]. We included both measures as
individuals with normal or low MMSE scores can have CDR scores between 0.0 and ≥1.0
(Supplementary Table 1). A total of 360 participants were identified with normal cognitive
status, 98 mild-cognitive impairment, and 71 with severe cognitive impairment.

Author Manuscript

Diagnoses of dementia were made by consensus during a conference of physicians,
psychologists, and social workers, who discussed all ancillary information and followed
the diagnostic strategy developed for the Washington Heights-Inwood Columbia Aging
Project in New York [19]. Besides having a CDR score of 1 or higher to define dementia
[30], individuals had cognitive impairment resulting in a functional decline in their social
or occupational activities from their previous level of functioning, not explained by
other conditions. Dementia diagnoses were classified as AD, Vascular dementia, or other
dementia, based on standardized criteria for each illness in the Diagnostic and Statistical
Manual of Mental Disorders (4th Edition) and specific criteria for each dementia subtype
[15]. MMSE scores are significantly associated to the diagnosis of dementia (Supplementary
Table 2).
Statistical analyses

Author Manuscript

Descriptive information is presented as mean ± standard deviation, and frequency as a
percentage (%). We calculated the relative frequency of NPI symptoms according to
cognitive status and dementia, and a between-group comparison was made with the Chi
square test. The contrast between groups for continuous variables was made with analysis
of variance (ANOVA) followed by Tukey post-hoc test. To define the independence among
NPI items, we used a principal component factor analysis with Oblimin rotation and Kaiser
normalization; components were based on a loading of 0.5 or greater. To determine the
association of each of the NPI symptoms with cognitive status, two logistic regression
models were designed (normal versus mild/moderate cognitive impairment, and normal
versus severe cognitive impairment). The models used the cognitive status (Mild/Moderate
or Severe Cognitive Impairment) as the exposure/dependent variable and the presence/
absence of each NPI symptom as the independent variable adjusted by sex, age, education,
alcohol habits, obesity, serum glucose levels, serum total cholesterol levels, previous stroke,
and conventional hypertension. The selection of covariables was based on the comparison of

J Alzheimers Dis. Author manuscript; available in PMC 2021 August 10.

Gil et al.

Page 5

Author Manuscript

clinical characteristics among categories of cognitive status, and variables with a p-value ≤
0.15 were selected as potential confounders.
We conducted a receiver-operating characteristic curve analysis to determine the area
under the curve (AUC) to discriminate between participants with normal cognitive status
versus those with mild/moderate-and severe cognitive impairment, and participants with
and without dementia. Two models were designed, the basic model that accounted for sex,
age, education, alcohol habits, obesity, serum glucose levels, serum total cholesterol levels,
previous stroke, and conventional hypertension, and the second model included in addition
to potential confounders, the NPI symptoms. Statistical analyses were performed using
SPSS software, and statistical significance was accepted at p < 0.05.

RESULTS
Author Manuscript

Demographic characteristics
Table 1 lists the characteristics of the 529 participants included in the present study.
The mean age was 59.3 years old, and 71.8% (n = 380) of participants were women.
The proportion of dementia was 6.8% (n = 36). Across categories of cognitive status
(from normal, mild/moderate, and severe cognitive status), individuals with severe cognitive
impairment were 13 years older than those with normal cognition (p = 0.029), had 7 years
less of education (p < 0.001), had lower proportions of alcohol habits (p < 0.001) and
obesity (p = 0.025), higher serum levels of glucose and total cholesterol (p < 0.05). The
proportions of women (p < 0.001) and conventional hypertension (p = 0.021) were higher.
Over 50% of individuals with severe cognitive impairment also had a dementia diagnosis,
whereas no individuals had this diagnosis in the other cognitive categories (p < 0.001).

Author Manuscript

NPI domains and cognitive status

Author Manuscript

In the total sample, more than 50% of the participants had at least one neuropsychiatric
symptom (Table 2). The most frequent neuropsychiatric symptoms in the normal cognition
group were sleep disturbances (30.3%), anxiety (25.6%), and depression (19.7%). In the
mild/moderate cognitive impairment group, the most frequent neuropsychiatric symptoms
were the same as in the normal control group, except that the proportion of those
experiencing those symptoms was marginally higher: sleep alterations (37.1%), anxiety
(34.7%), and depression (25.5%). Finally, the same symptoms were the most frequent in the
severe cognitive impairment group, but depression was the most common (33.8%), followed
by anxiety (28.2%) and sleep disturbances (25.7%). It is noteworthy that hallucinations were
present in the three groups, but the higher occurrence was found in the group of severe
cognitive impairment (21.1%).
Because neuropsychiatric symptoms tend to co-occur, we investigated the possibility of
reducing the NPI data into clusters of symptoms. We used principal component analysis
(Oblimin rotation) after testing for suitability of the data to proceed with factor analysis
(Bartlett’s test of sphericity, p = 0.001, and Kaiser’s measure of sampling adequacy =
0.62). Using the criterion of eigenvalues > 1.0, the 12 symptoms were reduced to five
factors or components that explained 63.5% of the total variance in the data (Supplementary
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Table 3). The first component (22.5% of total variance) denoted a dimension representing
‘apathy’ and had high loadings on apathy, eating abnormalities, and aberrant motor behavior.
The second component represented a ‘nighttime disturbances’ dimension, including
nighttime disturbances and irritability. The third factor represented a ‘psychosis’ dimension,
and had high loadings for delusions, hallucinations, and aberrant motor behavior. The
fourth factor represented an ‘affective’ dimension and had high loadings on anxiety,
depression, irritability, disinhibition, and agitation/aggression. The fifth factor represented
a ‘hyperactivity’ dimension, and had high loadings of euphoria, agitation/aggression, and
aberrant motor behavior. Because of three of the neuropsychiatric symptoms (aberrant motor
behavior, agitation/aggression, and irritability) loaded in more than one component, we
analyzed the association between each individual symptom in the different groups defined
by cognitive status and adjusting for potential confounders.

Author Manuscript

After adjustment for sex, age, education, alcohol habits, obesity, serum glucose levels, serum
total cholesterol levels, and hypertension, aberrant motor behavior (OR, 8.11; CI, 1.15–17.3;
p = 0.036) and agitation/aggression (OR, 4.10; CI, 1.44–11.7; p = 0.008) were the main NPI
domains related to cognitive status defined by MMSE and CDR scores (Table 3).
NPI domains and dementia
The most frequent neuropsychiatric symptoms in individuals clinically diagnosed as having
dementia were anxiety (39.1%) and depression (38.9%), followed by sleep disturbances
(34%), The dementia group showed a significantly higher frequency of aberrant motor
behavior (p < 0.001), agitation/aggression (p < 0.001), delusions (p < 0.001), irritability (p <
0.014), depression (p < 0.016), eating disorders (p < 0.012), and hallucinations (p = 0.033)
than the dementia-free group (Fig. 1).

Author Manuscript

After accounting for potential confounders, the presence of aberrant motor behavior,
agitation/aggression, delusions, irritability symptoms, an eating disturbance significantly
associated with higher probability of having dementia by 4.25 (CI, 1.01–19.6; p = 0.043),
6.22- (CI, 2.27–17.1; p < 0.001), 4.91-(95% CI 1.43–16.9; p = 0.012), 4.65 (CI, 1.81–12.0; p
= 0.002), and 3.80 (CI, 1.42–10.0; p = 0.008) fold-increase; respectively (Fig. 2).
Area under the curve for cognitive status and dementia

Author Manuscript

Using the receiver-operating characteristics curve analysis, the addition of the
neuropsychiatric symptoms collected with the NPI does not improve the sensitivity of the
diagnosis of mild/moderate cognitive impairment. However, including the NPI significantly
improves the discrimination of severe and cognitive impairment and dementia (Fig. 3).
The inclusion of NPI scores in a basic model that accounted for sex, age, education,
alcohol habits, obesity, serum glucose levels, serum total cholesterol levels, and conventional
hypertension significantly improved the AUC from 0.93% to 0.95% for severe cognitive
impairment (p < 0.003) and from 0.87% to 0.91% for dementia (p < 0.05).

DISCUSSION
Neuropsychiatric symptoms in older adults are frequent reasons for consultation in
low resource settings. Because of its population base, sample size, and comprehensive
J Alzheimers Dis. Author manuscript; available in PMC 2021 August 10.
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participant characterization, the MAS can provide insights into the prevalence of
neuropsychiatric symptoms and its relationship to cognitive impairment in a Hispanic
population, with low levels of education. We explored which of these symptoms were
associated with mild/moderate and severe cognitive impairment and also if the recording of
them with the NPI improves the sensitivity of a diagnosis based on global assessment tools
(MMSE + CDR). Results confirmed higher rates of neuropsychiatric symptoms in the group
with severe cognitive impairment and dementia, and intermediate prevalence among those
with mild/moderate cognitive impairment in comparison with the normal cognition group.

Author Manuscript

We found that more than 50% of Hispanic cohort had at least one neuropsychiatric
symptom. The prevalence estimates are comparable with prior population-based estimates,
after considering some methodological differences [16–19]. Furthermore, the high
prevalence of neuropsychiatric symptoms in the overall population was similar to the
report by Salazar et al. (2015) [18]. In fact, out of the 12 symptoms, all but four were
similar across all the cognitive groups, categorized either clinically or by global assessment
measures. Sleep disturbances and anxiety were the most common symptoms in the normal
cognition group affecting almost one third of participants, and not significantly different
from the groups with cognitive impairment; this is similar to the reports of population-based
cohorts in Spain [20] and Brazil [21]. Interestingly, disinhibition in the form of socially
inappropriate comments and/or actions was barely reported, even within the group of severe
cognitive impairment with an overall prevalence of 0.2%. It is possible that there is a cultural
acceptance of age-related changes in the “freedom” of self-expression via speech or action,
humor styles, or shame in reporting sexual disinhibition in this population.

Author Manuscript

After adjustment for potential confounders, none of the neuropsychiatric symptoms was
significantly associated to mild/moderate cognitive impairment and only aberrant motor
behavior and agitation/aggression were significantly associated with severe cognitive
impairment. Aberrant motor behavior, such as s wandering away from home or repetitive,
purposeless behaviors were present in about 2% of our cohort, reaching 8% in severe stages
of cognitive impairment which is relatively lower than reported in Mexican-Americans [18]
and others [22], but is relatively similar to the Brazilian report [21]. Agitation/aggression
was found in about 9% of the cohort, but 18% among participants with severe cognitive
impairment, this prevalence is almost half of what has been reported in Mexican Americans,
but similar to the Brazilian report [21].
Consistently, addition of the neuropsychiatric symptoms added value to the global
assessment strategy only for the diagnosis of severe cognitive impairment.

Author Manuscript

In terms of distinguishing features none of the neuropsychiatric symptoms was found
to be more prevalent among those with mild/moderate cognitive impairment in contrast
with the normal cognition group. After accounting for potential confounders, aberrant
motor behavior, agitation/aggression, delusions, irritability and eating disturbance were
significantly associated with dementia.
Improving precision of the clinical diagnosis is key to diminish the burden of dementia.
The MMSE scores and cerebrospinal fluid (CSF)-tau levels are useful in the diagnosis of
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AD [23]. If these two phenotypes are incorporated within the patient’s medical history,
risk assessment, neuro-logical examination, and biomarkers such APOE genotype, there
is approximately a 90% improvement of the dementia diagnosis [24]. However, the
incorporation of neuropsychiatric, psychological, and behavioral symptoms might improve
diagnostic accuracy, but data is scarce. We found that inclusion of NPI information
significantly improved model performance of dementia diagnosis, as well as diagnosis of
severe but not mild/moderate cognitive impairment.

Author Manuscript

Neuropsychiatric information is critical to the clinical management of dementias [25],
which justified the inclusion of NPI profile into diagnostic approaches [3, 4]. Indeed, in
individuals with MCI, the NPI profile improved the prediction of dementia progression
[3,4]. However, these studies lack of Hispanics cohorts (0% from 6%). Based on our
findings, the NPI profile might benefit the accuracy of dementia diagnosis in Hispanics.
Interestingly, behavioral disturbances are more prominent compared to cognitive symptoms
in the early-onset dementias, which may lead to missed cases or misdiagnosis [26].
Moreover, Watermeyer and Calia (2019) correctly note that the conceptual shift from
cognitive aspects of AD to biological/biomarker-based approaches is challenging for lowand middle-income countries that may lack the resources and expertise to implement novel
and costly diagnostic and intervention strategies [27].

Author Manuscript

Cognitive impairment was associated with the presence of neuropsychiatric symptoms in
two NPI domains. Specifically, severe cognitive impairment was associated with aberrant
motor behavior and agitation/aggression, which is usually linked with brain deterioration in
more advanced stages of dementia [28]. Cummings et al. [11] reported positive correlations
between MMSE scores and NPI delusions, anxiety, disinhibition, and aberrant motor
behavior in non-Hispanic AD patients [10]. Interestingly, these authors also found that
dementia-free control subjects with abnormal MMSE scores had higher NPI scores in their
study, although they did not specify which NPI domains. Moreover, Royall and Palmer
[29] recently reported that a latent dementia phenotype (δ) is associated with multiple
behavioral and psychological disturbances, and that these associations are linked to general
intelligence and not to domain-specific pathologies (e.g., domain-specific memory, executive
function). The inclusion of Mexican-Americans in this study is commendable, and suggests
that the relationship between cognitive function and psychological/behavioral disturbances
in Hispanics/Latinos is an important topic that merits further study.

Author Manuscript

Our results are consistent with previous studies that examined neuropsychiatric symptoms in
relation to cognitive status and dementia in non-Hispanic populations [3, 5]. For example,
a study of elderly subjects in Minnesota found that MCI increased the prevalence of most
NPI symptoms: 50% of individuals with MCI had at least one neuropsychiatric symptom,
compared to 25% of those with normal cognition [16]. Another study of mostly Caucasian
subjects in the US reported a relationship between neuropsychiatric symptoms and MCI,
and also found that more subjects with dementia exhibited neuropsychiatric symptoms
than non-demented individuals [30]. Our findings are particularly consistent with Salazar
et al. [31] who reported that among individuals with AD, Mexican Americans had higher
NPI behaviors than non-Hispanics; there were no differences between ethnic groups for
individuals with clinically diagnosed MCI.
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The relationship between anxiety and cognitive impairment in dementias is complex and
understudied [32]. For example, Scaricamazza et al. [33] reported higher anxiety scores
associated with MCI than AD. Interestingly, in the present study, anxiety scores were highest
in the moderate/mild cognitive impairment group (34.7%) compared to normal cognition
(25.6%) and severe cognitive impairment (28.2%) groups. Ma [32] notes that anxiety
has been studied less compared to depression; that results of various studies regarding
anxiety-cognition interactions have been mixed, and that the concept of anxiety requires
special consideration. Indeed, there are different types of anxiety [32], and others have
proposed that anxiety interacts with other NPI domains. For example, Forrester et al. [4]
used latent class analysis and found two behavioral clusters that contain anxiety: a severe
cluster (anxiety with agitation) and an affective cluster (anxiety with depression). These
results suggest that the relationship between anxiety and cognitive status in AD and related
dementias is dependent on other psychological factors, and these interactions might impact
mental health outcomes.

Author Manuscript
Author Manuscript

The present study must be interpreted within the context of its potential limitations. First,
the cross-sectional design does not allow to infer causality, but rather associations between
NPI domains, cognitive status, and dementia. Analysis of longitudinal data is needed to
replicate our results in terms of risk-development of cognitive decline and dementia. The
external validity of our findings will be corroborated with studies of the applicability of
NPI instruments in other Hispanic populations. Second, the study included a low number
of individuals with dementia at baseline. Given the longitudinal nature of the MAS, we
would expect that in participants with normal cognitive status (defined by an MMSE above
23 points), the presence of neuropsychiatry symptoms predicts the incidence of dementia.
Third, we did not implement CSF or neuroimaging biomarkers in the diagnosis of dementia;
however, the clinical diagnosis case is one of our study’s strengths. This study has several
strengths to highlight and, given the longitudinal nature of the MAS, this cross-section
analysis will help to define variables considered risk and confounders for follow up. Our
multidisciplinary team encompassed physicians, including general practitioners, internal
medicine, geriatrics, neuropsychiatry, neurologists, nurses, social workers, and psychologists
for evaluation and analysis of the findings. Another strength of the MAS is the available
data on cardiovascular risk factors. There is considerable evidence that cardiovascular risk
factors, including hypertension or diabetes, are associated with psychosocial behavior and
cognitive decline in the general population and patients with dementia [34, 35] and the
development of dementia. We were then able to adjust our analyses by these two potential
confounders. Finally, the MAS included Hispanic participants from a developing country.
Although Hispanics share some sociocultural experiences and genetic/biological factors,
Hispanics are not a monolithic group [36]. In fact, the prevalence of neuropsychiatric
symptoms in Hispanics and Latinos in the US is influenced by familial country of origin
[37]. Also, multicultural influences and local admixture might play a role in the observed
results, and the possible between-group differences should be considered before aggregating
data.
In conclusion, we found that neuropsychiatric symptoms relate to groups with variate
cognitive impairment and dementia in Hispanic adults of the MAS, Venezuela. Our study
provides new insight regarding the mental health status of a rapidly growing minority in
J Alzheimers Dis. Author manuscript; available in PMC 2021 August 10.
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relation to dementia—one of the major public health diseases in older adults. Therefore,
implementation of NPI instruments within the clinical practice might help identify and
stratify patients at high risk of developing dementia. The general agreement of our findings
with results of previous studies on non-Hispanic populations is encouraging, since Hispanics
have been underrepresented in clinical research [38], and the similarity suggests that
some findings might generally apply to different populations. Although longitudinal data
are needed to replicate our results in terms of risk-development of cognitive decline
and dementia, the applicability of NPI instruments in other populations supports the
implementation of the assessment of neuropsychiatric symptoms in Hispanic populations.

Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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The proportion of neuropsychiatric symptoms in subjects with and without dementia at
baseline. Neuropsychiatric Inventory (NPI). p-values are for the differences between groups.
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Fig. 2.

Association between NPI domains and dementia. NPI, Neuropsychiatric Inventory; OR,
odds ratios; CI, confidence interval. Models accounted for sex, age, education, alcohol
habits, obesity, serum glucose levels, serum total cholesterol levels, previous stroke, and
conventional hypertension. Statistics were not computed for disinhibition due to absence of
symptoms for these categories.
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Receiver Operating Characteristics Curve for Neuropsychiatric Inventory (NPI) to
Discriminate Individuals with and without Mild-Cognitive (A), Severe Cognitive
Impairment (B), and Dementia (C). AUC, area under the curve. Basic model accounted
for sex, age, education, alcohol habits, obesity, serum glucose levels, serum total cholesterol
levels, and conventional hypertension.
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Use of anti-hypertensive treatment, n (%)

History of CVD, n (%)

Previous stroke, n (%)

Prevalence of dementia
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Mild/Moderate Cognitive Impairment

36 (50.7)

2 (2.8)

7 (9.9)

24 (33.8)

<0.001

0.087

0.761

0.316

0.002

In post hoc analyses, using the Tukey’s test, we found that serum glucose and total cholesterol were different between normal versus severe cognitive impairment (p = 0.035, and p = 0.032).

‡

p-value of the comparison of characteristics among categories of cognitive status defined by MMSE.

†

0.92 ± 0.42

0.134

0.030

‡

0.767

0.063

0.001

0.195

<0.001

<0.001

0.046

205.7 ± 44.9

54 (76.1)

†

0.079

p

‡

118.2 ± 50.5
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17 (23.9)

19 (26.8)

28 (39.4)

2.1 ± 2.5

69.6 ± 13.1

52 (73.2)

(N =71)

Severe Cognitive Impairment

Cognitive Status Defined

Normal was a MMSE between 24 and 30, mild-cognitive impairment between 18 and 23, and severe cognitive below 17.

*

CVD, cardiovascular diseases.

CDR ≥ 1, n(%)

0.87 ± 0.30
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Diabetes mellitus, n (%)

191.8 ± 45.9
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Serum total cholesterol, mg/dL
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Alcohol intake, n (%)

108.4 ± 36.8
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History of smoking, n (%)

Serum glucose level, mg/dL

7.21 ± 4.7
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Education, y

380(71.8)
59.3 ± 13.5

Age, y
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1 (0.2)

Disinhibition

1 (0.3)

1 (0.3)

39(10.8)

71 (19.7)

48 (13.4)

16 (4.4)

23 (6.4)

27 (7.5)

2 (0.6)

31 (8.6)

110(30.6)

92 (25.6)

(n = 360)

Normal Cognition

0 (0.0)

0 (0.0)

13 (13.3)

25 (25.5)

13 (13.3)

3(3.1)

9 (9.2)

7(7.1)

2 (2.0)

14 (14.3)

36(37.1)

34 (34.7)

(n = 98)

Mild/Moderate-Cognitive Impairment

Cognitive Status*

0 (0.0)

3 (4.23)

11 (15.5)

24 (33.8)

13 (18.3)

7 (9.9)

7 (9.9)

13 (18.3)

6 (8.4)

15(21.1)

18 (25.7)

20 (28.2)

(N=71)

Severe Cognitive Impairment

†

0.528

0.003

0.231

0.007

0.357

0.146

0.220

0.013

<0.001

0.001

0.804

0.294

p

p-value of the comparison of characteristics among categories of cognitive status defined by MMSE and CDR scores.

†

Cognitive status was defined based on the MMSE and CDR scores. Participants with (i) CDR = 0 (normal) and normal or low MMSE scores; or (ii) CDR = 0.5 but normal MMSE score were defined
as normal cognition. Mild-cognitive impairment included individuals with (i) CDR = 0 but very-low MMSE scores; or (ii) CDR = 0.5 with low MMSE score; or (iii) CDR= 1 but normal MMSE score.
Severe cognitive impairment included individuals with (i) CDR = 1 and low or very-low MMSE score; or (ii) CDR = 0.5 but very-low MMSE score; or (iii) CDR ≥ 2. The MMSE between 24 and 30 was
categorized as normal, low between 18 and 23, and very-low cognitive below 17.

*

NPI, Neuropsychiatric Inventory. Frequencies (n) and proportion (%) indicates the number of participants with one or more neuropsychiatric symptoms.

4 (0.8)

Euphoria

26 (4.9)

Delusions

63 (11.9)
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Eating disturbances
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Agitation/aggression
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Aberrant motor behavior
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Hallucinations

Depression

164 (31.2)

Nighttime disturbances

Irritability

146 (27.6)

(n = 529)

Whole Population

Anxiety

NPI Symptoms, n (%)

Prevalence of Neuropsychiatric Symptoms According to Cognitive Status Defined by MMSE and CDR Scores
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†

0.88 (0.48–1.59)
1.03 (0.49–2.18)

Irritability

Depression

Eating

‡
NA

NA

‡

‡

0.933

0.661

0.798

0.438

0.664

0.937

0.782

0.465

0.855

0.827

p

‡
NA

‡
NA

2.60 (0.91–7.42)

1.20 (0.54–2.64)

1.98 (0.79–5.00)

2.19 (0.55–8.77)

1.64 (0.51–5.30)

4.10(1.44–11.69)

8.11 (1.15–17.34)

1.70 (0.63–4.65)

0.45 (0.20–1.04)

0.74 (0.33–1.64)

ORs (95% CI)*

NA

NA

‡

‡

0.075

0.659

0.147

0.267

0.407

0.008

0.036

0.298

0.062

0.457

p

Normal (n = 326) versus Severe Cognitive Impairment (n = 71)
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Models did not compute statistics due to the low/absent number of cases within groups.

Models accounted for sex, age, education, alcohol habits, obesity, serum glucose levels, serum total cholesterol levels, and hypertension.

‡

†

Cognitive status was defined based on the MMSE and CDR scores. Participants with (i) CDR = 0 (normal) and normal or low MMSE scores; or (ii) CDR = 0.5 but normal MMSE score were defined
as normal cognition. Mild-cognitive impairment included individuals with (i) CDR = 0 but very-low MMSE scores; or (ii) CDR = 0.5 with low MMSE score; or (iii) CDR= 1 but normal MMSE score.
Severity cognitive impairment included individuals with (i) CDR= 1 and low or very-low MMSE score; or (ii) CDR = 0.5 but very-low MMSE score; or (iii) CDR > 2. The MMSE between 24 and 30 was
categorized as normal, low between 18 and 23, and very-low cognitive below 17.

*

NPI, Neuropsychiatric Inventory; OR, odds ratios; CI, confidence interval; NA, not available.
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Delusions

Disinhibition
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Agitation/aggression
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Euphoria
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Hallucinations
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1.06(0.62–1.81)

ORs (95% CI)

Normal (n = 326) versus Mild/Moderate-Cognitive Impairment (n = 98)

Nighttime disturbances

Anxiety

Neuropsychiatric Symptoms

Cognitive Status*

Adjusted logistic regression model for the association between neuropsychiatric symptoms and cognitive status defined by MMSE and CDR scores
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